The spectrum of GH responses to GHRH and somatostatin in patients with acromegaly.

Hanew, Kunihiko; Sato, Shuichi; Goh, Meigan; Sasaki, Akira; Shimizu, Yasuyuki; Sugawara, Akira; Ohtsuka, Tsutomu; Yoshinaga, Kaoru

doi:10.1620/tjem.155.233

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…octreotide, even though GH secretion was inhibited by at least 40% in all unselected acromegalic patients, we also observed variation in GH suppression. Other series found generally lower numbers of octreotide responsive patients, varying from 56% to 67% (defined by a GH decrease of 50% or more) [8,20,21]. Generally, these patient series were smaller, and either native somatostatin-14 was infused intravenously, or octreotide was given subcutaneously, which may explain the observed discrepancies.…”

Section: Discussionmentioning

confidence: 88%

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly

Biermasz

Pereira

Smit

et al. 2005

Growth Hormone & IGF Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly

Biermasz

Pereira

Smit

et al. 2005

Growth Hormone & IGF Research

View full text Add to dashboard Cite

“…The autonomous secretion of GH caused by both endogenous (25) and exogenous progestins (13,14) in the dog is different from the situation in man, in which a large subset of acromegalie patients remains responsive to stimulation and/or inhibition (26). We demonstrated recently that the origin of the GH excess in the dog is not the pituitary gland but the mammary gland, in which progestins induce an ectopie production of GH in the ductular epithelium (27).…”

Section: Discussionmentioning

confidence: 92%

Progestin treatment in the dog I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis

Mol²,

Gr³

et al. 1994

European Journal of Endocrinology

View full text Add to dashboard Cite

The effects of two synthetic progestins, medroxyprogesterone acetate (MPA) and proligestone (PROL), on the release of growth hormone (GH) and glucose metabolism were studied in two groups of eight ovariohysterectomized dogs. Eight injections of long-acting progestins were administered at 3-week intervals. Recovery was studied in four dogs of each treatment group in the 6 months following cessation of progestin administration. Treatment with both MPA and PROL resulted in similar increases in plasma levels of GH and insulin-like growth factor I (IGF-I). The GH responses to both clonidine and growth hormone-releasing hormone became impaired. In neither treatment group did the elevated plasma GH levels decrease after administration of the synthetic somatostatin analogue SMS 201-995. The size and shape of the pituitary gland were not changed by progestin treatment. After cessation of progestin administration, basal plasma levels of GH and IGF-I did not return to pretreatment values. The GH response to growth hormone-releasing hormone remained impaired for at least 6 months after the last progestin administration. In both treatment groups, glucose homeostasis was sustained initially by increased insulin production. Prolonged treatment with MPA and PROL resulted in glucose intolerance. No amelioration was observed during the recovery period in either group. A small number of dogs developed diabetes mellitus. In more than 50% of the dogs in both treatment groups small mammary tumours developed. The recently discovered local production of GH probably played a role in mammary tumorigenesis.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly — The effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone

Utsumi

Hanew

Sugawara

et al. 1992

J Endocrinol Invest

View full text Add to dashboard Cite

It has been reported that paradoxical GH responses to corticotropin-releasing hormone (CRH) occur in only few patients with acromegaly. However, we have observed such responses in 7 of 14 active acromegalic patients. Therefore, we have studied the GH responses to thyrotropin-releasing hormone (TRH) (500 micrograms, iv), gonadotropin-releasing hormone (LHRH) (100 micrograms, iv) and GH-releasing hormone (GHRH) (100 micrograms, iv) in these patients to examine the relationships between the GH responses to CRH and the responses to these hypothalamic hormones. Further, these patients received human CRH (1-41) NH2 (100 micrograms, iv) with or without dexamethasone (Dex) pretreatment (1 mg/100 ml saline, iv, from -30 to +30 min) to study the mechanism of CRH-induced GH secretion, and a perifusion experiment was performed using adenoma tissue obtained at surgery from one patient (10(-7) M CRH and TRH were added) to elucidate whether CRH acts directly at the pituitary level. Aberrant GH responses induced by CRH were found in 7 of 14 (50%) acromegalic patients (TRH responders: 10/13, 77%; LHRH responders: 2/9, 22%; GHRH responders: 10/12, 83%). In these patients, percent GH increment induced by CRH ranged from 81 to 144% (Mean +/- SE, 118 +/- 8%), and the GH peak (19 +/- 3 min) appeared as early as after TRH (23 +/- 4 min, N = 10).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

The spectrum of GH responses to GHRH and somatostatin in patients with acromegaly.

Cited by 3 publications

References 11 publications

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly

Progestin treatment in the dog I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis

Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly — The effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone

Contact Info

Product

Resources

About